Literature DB >> 23836501

Fully automated radiosynthesis of 2-[18F]fludarabine for PET imaging of low-grade lymphoma.

Stéphane Guillouet1, Delphine Patin, Olivier Tirel, Jérôme Delamare, Fabienne Gourand, Jean Bernard Deloye, Michel Leporrier, Louisa Barré.   

Abstract

PURPOSE: An efficient and fully automated radiosynthesis of 2-[(18)F]fluoro-9-β-D-arabinofuranosyl-adenine (2-[(18)F]fludarabine, [(18)F]-5) based on a GE TRACERlab™ FX-FN module has been developed. PROCEDURES: A 2-nitro purine derivative 3 was developed as precursor for labeling with fluorine-18. The radiosynthesis of [(18)F]-5 was performed in two steps in a single reactor with an intermediary purification on Sep-Pak® silica which involved the addition of a three-way valve on the original module. After hydrolysis, [(18)F]-5 was purified by semi-preparative high-pressure liquid chromatography (HPLC) and a quality control was established.
RESULTS: The labeling precursor 3 was obtained in 45% overall yield. Nucleophilic substitution with K(18)F/K2.2.2 afforded protected 2-[(18)F]fludarabine ([(18)F]-4) in 73 ± 4%, radiochemical yield (decay corrected to the end of bombardment (EOB)) and based on the initial [(18)F]F(-) activity. An aqueous ammonia/methanol solution was used for the deprotection reaction and gave the desired [(18)F]-5 in 67 ± 3% yield after 20 min at 70 °C based on HPLC profile.
CONCLUSIONS: The process afforded pure 2-[(18)F]fludarabine in 48 ± 3% yield (decay corrected to the EOB) in 85 min, with a specific activity of 310 ± 72 GBq/μmol at the end of synthesis (EOS) and a radiochemical purity up to 99%.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23836501     DOI: 10.1007/s11307-013-0657-4

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  12 in total

1.  Fludarabine phosphate: A DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity.

Authors:  E R Goodman; P S Fiedor; S Fein; E Athan; M A Hardy
Journal:  Am Surg       Date:  1996-06       Impact factor: 0.688

2.  Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU.

Authors:  Alfons Verbruggen; Heinz H Coenen; Jean-Robert Deverre; Denis Guilloteau; Bengt Langstrom; Piero A Salvadori; Christer Halldin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11       Impact factor: 9.236

3.  A color spot test for the detection of Kryptofix 2.2.2 in [18F]FDG preparations.

Authors:  B H Mock; W Winkle; M T Vavrek
Journal:  Nucl Med Biol       Date:  1997-02       Impact factor: 2.408

Review 4.  Cellular and clinical pharmacology of fludarabine.

Authors:  Varsha Gandhi; William Plunkett
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

Authors:  N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield
Journal:  J Clin Oncol       Date:  1999-12       Impact factor: 44.544

Review 6.  Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients.

Authors:  L G Strauss
Journal:  Eur J Nucl Med       Date:  1996-10

7.  Efficient radiosynthesis of 2-[(18)f]fluoroadenosine: a new route to 2-[(18)f]fluoropurine nucleosides.

Authors:  Patrice Marchand; Christophe Lorilleux; Gwénaëlle Gilbert; Fabienne Gourand; Franck Sobrio; Damien Peyronnet; Martine Dhilly; Louisa Barré
Journal:  ACS Med Chem Lett       Date:  2010-05-28       Impact factor: 4.345

Review 8.  Positron emission tomographic scans in lymphoma: convention and controversy.

Authors:  Stephen M Ansell; James O Armitage
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

9.  Thin layer chromatographic detection of kryptofix 2.2.2 in the routine synthesis of [18F]2-fluoro-2-deoxy-D-glucose.

Authors:  T Chaly; J R Dahl
Journal:  Int J Rad Appl Instrum B       Date:  1989

Review 10.  The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin's and non-Hodgkin's lymphoma survivors: a systematic review.

Authors:  Simone Oerlemans; Floortje Mols; Marten R Nijziel; Marnix Lybeert; Lonneke V van de Poll-Franse
Journal:  Ann Hematol       Date:  2011-06-14       Impact factor: 3.673

View more
  6 in total

1.  2-[18F]fludarabine, a novel positron emission tomography (PET) tracer for imaging lymphoma: a micro-PET study in murine models.

Authors:  Martine Dhilly; Stéphane Guillouet; Delphine Patin; Fabien Fillesoye; Ahmed Abbas; Fabienne Gourand; Olivier Tirel; Françoise Galateau; Eric T MacKenzie; Charles Dumontet; Michel Leporrier; Louisa Barré
Journal:  Mol Imaging Biol       Date:  2014-02       Impact factor: 3.488

2.  Evaluation of the specificity of [(18)F]fludarabine PET/CT in a xenograft model of follicular lymphoma: comparison with [(18)F]FDG and impact of rituximab therapy.

Authors:  Narinée Hovhannisyan; Stéphane Guillouet; Fabien Fillesoye; Martine Dhilly; Delphine Patin; Françoise Galateau; Michel Leporrier; Louisa Barré
Journal:  EJNMMI Res       Date:  2015-04-14       Impact factor: 3.138

3.  [18F]Fludarabine-PET in a murine model of multiple myeloma.

Authors:  Narinée Hovhannisyan; Martine Dhilly; Martin Fidalgo; Fabien Fillesoye; Stéphane Guillouet; Brigitte Sola; Louisa Barré
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

4.  [18F]Fludarabine-PET as a promising tool for differentiating CNS lymphoma and glioblastoma: Comparative analysis with [18F]FDG in human xenograft models.

Authors:  Narinée Hovhannisyan; Fabien Fillesoye; Stéphane Guillouet; Méziane Ibazizene; Jérôme Toutain; Fabienne Gourand; Samuel Valable; Benoit Plancoulaine; Louisa Barré
Journal:  Theranostics       Date:  2018-08-10       Impact factor: 11.556

5.  Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma-a narrative review.

Authors:  Simone Krebs; Julia G Barasch; Robert J Young; Christian Grommes; Heiko Schöder
Journal:  Ann Lymphoma       Date:  2021-06-30

Review 6.  [18F]-Fludarabine for Hematological Malignancies.

Authors:  Louisa Barré; Narinée Hovhannisyan; Caroline Bodet-Milin; Françoise Kraeber-Bodéré; Gandhi Damaj
Journal:  Front Med (Lausanne)       Date:  2019-04-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.